PolyU has received funding support from the Research Grants Council (RGC)’s Strategic Topics Grant (STG) 2025/26 for a multidisciplinary biomedical project. The project aims to develop an integrated technology platform for next-generation cancer immunotherapy. Led by Prof. ZHAO Yanxiang—Associate Head and Professor of PolyU’s Department of Applied Biology and Chemical Technology (ABCT)—this pioneering research addresses some of the most pressing challenges in cancer treatment and has been awarded HK$32.4 million in RGC funding.
Prof. ZHAO Yanxiang’s team proposes building an integrated technological platform to develop Peptide-based Immunogenic Neoantigen Vaccines (PIN-Vax). This initiative will target cancer types that currently show a limited response to immune checkpoint inhibitors (ICIs) and chimeric antigen receptor-T cell therapy (CAR-T). The long-term goal is to transform this platform into an innovative engine for next-generation cancer immunotherapy, ultimately benefiting cancer patients.
For more details, please refer to https://polyu.me/44Qq8F7.
